Literature DB >> 16398614

Polyethylene glycol (PEG) modified 99mTc-HMPAO-liposome for improving blood circulation and biodistribution: the effect of the extent of PEGylation.

Chang-Moon Lee1, Yongdoo Choi, Eun Jeong Huh, Ki Young Lee, Ho-Chun Song, Min Jung Sun, Hwan-Jeong Jeong, Chong-Su Cho, Hee-Seung Bom.   

Abstract

Modification of liposomes using polyethylene glycol (PEG) results in steric hindrance to the phagocyte system and prolongation of blood circulation time. However, PEGylation can reduce radiolabeling efficiency (RE) when using the glutathione method for radiolabeling the liposomes. Therefore, we investigated the effect of the extent of PEGylation (PEG extent (PEGExt): 0, 5, 9.6, and 13.7 mol%) on the in vivo biodistribution of liposomes in Wistar rats, and RE with technetium-(99m) ((99m)Tc). PEGylated liposomes were prepared with egg phosphatidylcholine (egg PC, 1.85 mol%), cholesterol (1.0 mol%), and distearoylphosphatidylethanolamine-N-[polyethylene glycol] (DSPE-PEG; 0, 5, 9.6, and 13.7 mol%, respectively). The size distribution of the PEGylated liposomes was analyzed by a dynamic light scattering. The (99m)Tc-hexamethylpropylene-amine oxime ((99m)Tc-HMPAO) complexes were used for radiolabeling of preformed liposomes. The labeling efficiency and stability was analyzed with Sephadex G-15 column, and the biodistribution studies of (99m)Tc-liposomes after intravenous (i.v.) injection were also investigated with Wistar rats. The sizes of PEGylated liposomes decreased by increasing the PEGExt to 9.6 mol%, whereas sizes increased at 13.7 mol%. RE of (99m)Tc were greater than 90% for all PEGExt tested, and radiolabeling stability in human plasma was enhanced as a function of PEGExt. Liposomes without PEG were cleared rapidly from the blood and accumulated preferentially in the liver and the spleen. When PEGExt was increased, the accumulation in the organs decreased. This accumulation of PEG was maximized at 9.6 mol%. Accumulation of the liposomes in the spleen was increased again when PEGExt increased to 13.7 mol%. The splenic uptake of liposomes seemed to be dependent not only on PEGExt but also on the size of the liposomes. In conclusion, the PEG chains on the surface of liposome have no influence on the labeling efficiency, and the prolongation of circulation time was maximized at the 9.6 mol% of PEGylation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16398614     DOI: 10.1089/cbr.2005.20.620

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  9 in total

1.  Strategies to maximize liposomal drug loading for a poorly water-soluble anticancer drug.

Authors:  Wenli Zhang; Guangji Wang; James R Falconer; Bruce C Baguley; John P Shaw; Jianping Liu; Hongtao Xu; Esther See; Jianguo Sun; Jiye Aa; Zimei Wu
Journal:  Pharm Res       Date:  2014-10-30       Impact factor: 4.200

2.  Preparation of RGD-modified long circulating liposome loading matrine, and its in vitro anti-cancer effects.

Authors:  Xiao-yan Liu; Li-ming Ruan; Wei-wei Mao; Jin-qiang Wang; You-qing Shen; Mei-hua Sui
Journal:  Int J Med Sci       Date:  2010-06-14       Impact factor: 3.738

3.  In vivo evaluation of PEGylated ⁶⁴Cu-liposomes with theranostic and radiotherapeutic potential using micro PET/CT.

Authors:  Anncatrine Luisa Petersen; Jonas Rosager Henriksen; Tina Binderup; Dennis Ringkjøbing Elema; Palle Hedengran Rasmussen; Anne Mette Hag; Andreas Kjær; Thomas Lars Andresen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-12-08       Impact factor: 9.236

Review 4.  Nanotechnology for delivery of drugs to the brain for epilepsy.

Authors:  Margaret F Bennewitz; W Mark Saltzman
Journal:  Neurotherapeutics       Date:  2009-04       Impact factor: 7.620

5.  [(186)Re]Liposomal doxorubicin (Doxil): in vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft model.

Authors:  Anuradha Soundararajan; Ande Bao; William T Phillips; Ricardo Perez; Beth A Goins
Journal:  Nucl Med Biol       Date:  2009-05-07       Impact factor: 2.408

6.  Neutral Lipopolyplexes for In Vivo Delivery of Conventional and Replicative RNA Vaccine.

Authors:  Federico Perche; Rudy Clemençon; Kai Schulze; Thomas Ebensen; Carlos A Guzmán; Chantal Pichon
Journal:  Mol Ther Nucleic Acids       Date:  2019-07-30       Impact factor: 8.886

7.  Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targeting.

Authors:  Federico Perche; Vladimir P Torchilin
Journal:  J Drug Deliv       Date:  2013-03-07

Review 8.  Nanomedicine-based neuroprotective strategies in patient specific-iPSC and personalized medicine.

Authors:  Shih-Fan Jang; Wei-Hsiu Liu; Wen-Shin Song; Kuan-Lin Chiang; Hsin-I Ma; Chung-Lan Kao; Ming-Teh Chen
Journal:  Int J Mol Sci       Date:  2014-03-04       Impact factor: 5.923

9.  Nano Liposomes Labeled with (99m)Tc-HMPAO, a Novel Agent for Blood Pool Imaging.

Authors:  Kayvan Sadri; Salimeh Momenypoor; Vahid Reza Dabbagh Kakhki; Ramin Sadeghi; Kamran Aryana; Fariba Johari Daha; Seyed Rasoul Zakavi; Mahmoud Reza Jaafari
Journal:  Iran J Pharm Res       Date:  2015       Impact factor: 1.696

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.